RE:Forget news speculation; Mackie's report catapulted price!This is a game changer report!!!!!! Here's 2 excerpts from the report.
See what is said about the IND FDA approval. Appears to be just a mere pebble holding back a Mack Truck,
Phase II Clinical Update:U.S.–IND pushed out about two months On November 25, 2019, Theralase received a letter from the FDA placing the IND on Full Clinical Hold pending resolution of specific deficiencies identified in the letter. Theralase is currently addressing these deficiencies and expects to provide the FDA with a Clinical Hold Complete Response prior to December 31, 2019 for review by the FDA. Subject to FDA review and approvalof the Clinical Hold Complete Response, Theralase should be in a position to receive FDA IND approval in early 2020
I need an explanation but to explain a valuation would seem to me they are justifying the $.80 target price. That alone should create an easy SP ascention to 50-60 cents.
Valuation
We valued TLT using a two-stage probability-adjusted DCF methodology. We discounted the pro forma net cash flow from 2019 to 2030 and used a terminal value in 2030. We have understood TLD-1433 would be launched in 2023. During the clinical stage of TLD-1433 (from present to 2022), we applied a discount rate of 60% to represent development risk –this rate has taken a probability of success for TLD-1433 into consideration. During the commercial stage of TLD-1433 (from 2023 to 2030), we used a WACC rate of 13%. Our WACC calculation was based on TLT’s beta value of 1.02 (source: Bloomberg), the 20-year Treasury rate of 4.64%, and the 20-year average annual return of the S&P/TSX composite total return index (6.60%). TLT currently has zero debt on its balance sheet. To calculate the terminal value of the net cash flow in 2030, we conservatively presumed a perpetual growth rate of 1%